A41 A40
Conditions
Interventions
Group 1: Patients with Sepsis
Group 2: Patients before and after large surgery
Group 3: Healthy probands
Sponsors
Klinik für AnästhesiologieUniversitätsklinikum Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with Sepsis: Consent by the legal representative; At least 2 SIRS criteria met: - temperature 38ºC - tachycardia (> 90 /min) - leukocytosis (> 12,000 /µl) OR leukopenia (10% immature blasts) - Tachypnea (> 20 /min) OR paCO2 <32 mmHg OR oxygenation index (FiO2/paO2) <200 OR mechanical Ventilation; Clinical or microbiological evidence of infection Sepsis-associated organ dysfunction indicated by a change in the Sequential Organ Failure Assessment (SOFA) score by 2 or more points (compared to previous day) Patients after surgery: Informed consent; Elective major surgery scheduled. Healthy volunteers: Informed consent.
Exclusion criteria
Exclusion criteria: Common exclusion criteria of all study groups: Pregnancy; Inclusion in an interventional study; infectious viral diseases (HBV, HCV, HIV); Iatrogenic immunosuppression. Specific exclusion criteria of patients with sepsis: Diagnosis "sepsis" >24 h. Specific exclusion criteria of healthy volunteers: One of the following states during the last 7 days: - Influenza infection or flu - Sports injuries or other trauma - Large-scale dental interventions (e.g., tooth extraction) - Blood or platelet donation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of the distribution of genome-wide histone modifications in isolated peripheral blood mononuclear cells (PBMCs) using chromatin immunoprecipitation sequencing | — |
Secondary
| Measure | Time frame |
|---|---|
| Measurement of global gene expression in isolated PBMCs using RNA-Seq, validated by qPCR Measurement of global DNA methylation in isolated PBMCs using microarray Measurement of metabolic pathways in isolated PBMCs using Seahorse™ Technology Measurement of phagocytic activity of immune cells using FACS Measurement of PBMCs functional competence for cytokine release by stimulation and ELISA phenotyping of immune cell populations using FACS Quantification of chemokines, cytokines, and metabolic metabolites in plasma by ELISA, or mass spectrometry Composition of the gastrointestinal microbiome using 16S sequencing Occurrence of secondary infections 28-day survival stay in hospital and intensive care unit | — |
Countries
Germany
Contacts
Public ContactMarkus A. Weigand
Klinik für AnästhesiologieUniversitätsklinikum Heidelberg
Outcome results
None listed